Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Shengxiang Ren et al.|The Lancet Oncology|2011Cited by 4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C. Zhou, Changxuan You, Yi‐Long Wu et al.|Annals of Oncology|2015Cited by 467
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G. Chen, Changxuan You, J. Feng et al.|Annals of Oncology|2013Cited by 120
Secretoglobin 1A member 1 (SCGB1A1) +38A/G polymorphism is associated with asthma risk: A meta-analysisWei Nie, Qingyu Xiu, Cheng Xue et al.|Gene|2013Cited by 18
Iconographies supplémentaires de l'article : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Yi‐Long Wu et al.|Unknown|2011Cited by 5